Exchange Announcement • 13 Oct 2026 08:15
Voluntary Announcement Insilico Medicine Nominates Peripheral-Restricted Vav1 Molecular Glue Degrader For Potential Treatment Of Autoimmune Diseases
Exchange Announcement • 30 Sep 2026 12:15
Voluntary Announcement Insilico Medicine Nominates Next-Generation Small Molecule Gipr Antagonist For Potential Intervention Of Obesity And Related Disorders
Exchange Announcement • 21 Sep 2026 12:26
Voluntary Announcement Insilico Medicine Entered Into An Ai Co-Development Collaboration With A Contract Value Up To Tens Of Millions Of U.S. Dollars To Build And Commercialize Foundation Models For Biology
Exchange Announcement • 14 Sep 2026 08:00
Voluntary Announcement Increase In Shareholding By Chairman Of The Board
Exchange Announcement • 10 Sep 2026 08:15